CVS Health Corporation (CVS)
NYSE: CVS · Real-Time Price · USD
56.83
+1.06 (1.90%)
Nov 20, 2024, 4:00 PM EST - Market closed
CVS Health Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for CVS Health stock have an average target of 73, with a low estimate of 58 and a high estimate of 94. The average target predicts an increase of 28.45% from the current stock price of 56.83.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CVS Health stock from 17 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 8 | 8 | 6 | 5 | 7 | 7 |
| Hold | 7 | 7 | 7 | 7 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 19 | 18 | 18 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Reiterates $76 → $67 | Strong Buy | Reiterates | $76 → $67 | +17.90% | Nov 20, 2024 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $60 → $66 | Hold → Buy | Upgrades | $60 → $66 | +16.14% | Nov 18, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $68 → $58 | Buy | Maintains | $68 → $58 | +2.06% | Nov 15, 2024 |
| UBS | UBS | Hold Maintains $60 → $62 | Hold | Maintains | $60 → $62 | +9.10% | Nov 7, 2024 |
| Barclays | Barclays | Buy Maintains $75 → $71 | Buy | Maintains | $75 → $71 | +24.93% | Nov 7, 2024 |
Financial Forecast
Revenue This Year
374.16B
from 356.62B
Increased by 4.92%
Revenue Next Year
390.95B
from 374.16B
Increased by 4.49%
EPS This Year
5.97
from 6.47
Decreased by -7.68%
EPS Next Year
6.91
from 5.97
Increased by 15.67%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 393.2B | 421.9B | 455.2B | ||
| Avg | 374.2B | 390.9B | 413.7B | ||
| Low | 357.4B | 369.3B | 389.0B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 10.3% | 12.8% | 16.4% | ||
| Avg | 4.9% | 4.5% | 5.8% | ||
| Low | 0.2% | -1.3% | -0.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 7.35 | 8.53 | 9.67 | ||
| Avg | 5.97 | 6.91 | 7.75 | ||
| Low | 4.90 | 5.47 | 5.90 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 13.6% | 42.7% | 40.0% | ||
| Avg | -7.7% | 15.7% | 12.2% | ||
| Low | -24.3% | -8.4% | -14.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.